Gene · 843
Papers2,703
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 2,703
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Integrated stress response (ISR) activation and apoptosis through HRI kinase by PG3 and other p53 pathway-restoring cancer therapeutics. | Oncotarget | 2024 | 39288289 | PubTator, text mining | PubMed |
| Strong activation of p53 by actinomycin D and nutlin-3a overcomes the resistance of cancer cells to the pro-apoptotic activity of the FAS ligand. | Apoptosis | 2024 | 39068622 | PubTator, text mining | PubMed |
| Study of the potential role of CASPASE-10 mutations in the development of autoimmune lymphoproliferative syndrome. | Cell Death Dis | 2024 | 38704374 | PubTator, text mining | PubMed |
| Targeting Colorectal Cancer: Unravelling the Transcriptomic Impact of Cisplatin and High-THC Cannabis Extract. | Int J Mol Sci | 2024 | 38674023 | PubTator, text mining | PubMed |
| Primary immune regulatory disorders (PIRD): expanding the mutation spectrum in Turkey and identification of sixteen novel variants. | Immunol Res | 2024 | 38644452 | PubTator, text mining | PubMed |
| SERT-StructNet: Protein secondary structure prediction method based on multi-factor hybrid deep model. | Comput Struct Biotechnol J | 2024 | 38596312 | PubTator, text mining | PubMed |
| Investigation of the effects of Theranekron and Sorafenib treatments on carcinogenesis, apoptosis and biochemical profile in hepatocellular carcinoma in rats. | Toxicol Mech Methods | 2024 | 38577837 | PubTator, text mining | PubMed |
| Paclitaxel and its semi-synthetic derivatives: comprehensive insights into chemical structure, mechanisms of action, and anticancer properties. | Eur J Med Res | 2024 | 38291541 | PubTator, text mining | PubMed |
| VEXAS syndrome is characterized by inflammasome activation and monocyte dysregulation. | Nat Commun | 2024 | 38291039 | PubTator, text mining | PubMed |
| Exploring the apoptotic effects of sericin on HCT116 cells through comprehensive nanostring transcriptomics and proteomics analysis. | Sci Rep | 2024 | 38287097 | PubTator, text mining | PubMed |
| Insights into How Plant-Derived Extracts and Compounds Can Help in the Prevention and Treatment of Keloid Disease: Established and Emerging Therapeutic Targets. | Int J Mol Sci | 2024 | 38279232 | PubTator, text mining | PubMed |
| Tumor microenvironment and immune system preservation in early-stage breast cancer: routes for early recurrence after mastectomy and treatment for lobular and ductal forms of disease. | BMC Immunol | 2024 | 38273260 | PubTator, text mining | PubMed |
| Autophagy and Apoptosis in Rabies Virus Replication. | Cells | 2024 | 38247875 | PubTator, text mining | PubMed |
| N-acetyltransferase NAT10 controls cell fates via connecting mRNA cytidine acetylation to chromatin signaling. | Sci Adv | 2024 | 38215194 | PubTator, text mining | PubMed |
| Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies. | Cell | 2024 | 38181741 | PubTator, text mining | PubMed |
| Contribution of HSP90 Cleavage to the Cytotoxic Effect of Suberoylanilide Hydroxamic Acid In Vivo and the Involvement of TXNIP in HSP90 Cleavage. | Biomol Ther (Seoul) | 2024 | 38148557 | PubTator, text mining | PubMed |
| Analysis of multiple programmed cell death-related prognostic genes and functional validations of necroptosis-associated genes in oesophageal squamous cell carcinoma. | EBioMedicine | 2024 | 38101299 | PubTator, text mining | PubMed |
| The Qi Yin San Liang San decoction enhances anti-CD19 CAR-T cell function in the treatment of B-cell lymphomas. | J Ethnopharmacol | 2024 | 37657771 | PubTator, text mining | PubMed |
| Programmed cell death in tumor immunity: mechanistic insights and clinical implications. | Front Immunol | 2023 | 38283351 | PubTator, text mining | PubMed |
| Autophagy-related mechanisms for treatment of multiple myeloma. | Cancer Drug Resist | 2023 | 38239705 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/843/papers?page=4